Surrozen (NASDAQ:SRZN) VP Sells $52,794.72 in Stock

Surrozen, Inc. (NASDAQ:SRZN) VP Yang Li sold 1,584 shares of Surrozen stock in a transaction on Monday, May 4th. The stock was sold at an average price of $33.33, for a total value of $52,794.72. Following the transaction, the vice president owned 17,216 shares in the company, valued at approximately $573,809.28. This represents a 8.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Surrozen Stock Down 9.9%

NASDAQ SRZN opened at $30.75 on Friday. Surrozen, Inc. has a 52 week low of $5.90 and a 52 week high of $35.00. The business’s fifty day simple moving average is $28.50 and its 200-day simple moving average is $22.38. The firm has a market cap of $353.32 million, a PE ratio of -0.82 and a beta of 0.59.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($11.65) EPS for the quarter, missing the consensus estimate of ($1.09) by ($10.56). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 4,810.50%.The company had revenue of $5.00 million for the quarter, compared to analysts’ expectations of $4.00 million. Research analysts expect that Surrozen, Inc. will post -4.04 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SRZN. Cantor Fitzgerald reissued an “overweight” rating and set a $40.00 price objective on shares of Surrozen in a research report on Tuesday, March 24th. HC Wainwright reissued a “buy” rating and set a $44.00 price objective (up from $36.00) on shares of Surrozen in a research report on Thursday. TD Cowen began coverage on Surrozen in a research report on Tuesday, April 21st. They set a “buy” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research report on Tuesday, April 21st. Finally, Wall Street Zen raised Surrozen from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Surrozen currently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Hedge Funds Weigh In On Surrozen

Hedge funds and other institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. lifted its stake in Surrozen by 50.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after purchasing an additional 500 shares during the last quarter. Persistent Asset Partners Ltd purchased a new stake in Surrozen during the fourth quarter worth approximately $99,000. Citadel Advisors LLC lifted its stake in Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after purchasing an additional 3,424 shares during the last quarter. Marshall Wace LLP purchased a new stake in Surrozen during the fourth quarter worth approximately $247,000. Finally, Geode Capital Management LLC lifted its stake in Surrozen by 22.6% during the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after purchasing an additional 5,702 shares during the last quarter. Hedge funds and other institutional investors own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.